• Phenacetin in Scientific Research: Applied Protocols & Troub

  2026-05-13

  Phenacetin (N-(4-ethoxyphenyl)acetamide) is a gold-standard probe for absorption and metabolism workflows, leveraging its unique solubility and stability profile. This article provides actionable protocols, advanced troubleshooting, and direct links to cutting-edge applications in organoid models and pharmacokinetic studies.

• ARCA Cy5 EGFP mRNA (5-moUTP): Precision for mRNA Delivery As

  2026-05-12

  ARCA Cy5 EGFP mRNA (5-moUTP) sets a new benchmark for quantifying mRNA delivery, localization, and translation efficiency in mammalian cells. Its dual fluorescent labeling and 5-methoxyuridine modification enable seamless workflow integration, minimize immune activation, and deliver actionable insights for mRNA system development.

• Acetylcysteine in 3D Co-Culture: Protocols for Oxidative Str

  2026-05-12

  Acetylcysteine unlocks robust modulation of oxidative stress pathways and chemoresistance in advanced 3D tumor-stroma models. This guide translates reference breakthroughs into actionable protocols, troubleshooting strategies, and workflow optimizations for translational research teams.

• Fosinopril Sodium: Advanced ACE Inhibitor Workflows in Hyper

  2026-05-11

  Fosinopril sodium is a unique phosphinic acid ACE inhibitor that empowers cardiovascular and renal research with reproducible blood pressure modulation and robust dual-route elimination. Leveraging its potent zinc ion binding and prodrug profile, this workflow guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven assay insights for translational hypertension and cardiovascular disease models.

• Metabolic Intervention Enhances Ferroptosis and Cuproptosis

  2026-05-11

  This study introduces a nanosystem-based strategy to sensitize tumor cells to both ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The approach not only improves the efficacy of regulated cell death in cancer therapy but also enhances anti-tumor immunity by remodeling the tumor immune microenvironment.

• Angiotensin 1/2 (2-7): Precision Tool for Translational RAS

  2026-05-10

  This thought-leadership article explores Angiotensin 1/2 (2-7) as a pivotal vasoconstrictor peptide for advanced blood pressure and viral pathogenesis research. We synthesize mechanistic insights, assay protocols, and translational guidance, referencing recent breakthroughs—including the peptide's role in SARS-CoV-2 spike–AXL binding—to inform next-generation cardiovascular and virology models. The article positions APExBIO’s high-purity Angiotensin 1/2 (2-7) as a field-leading research tool, highlighting its validated performance and offering workflow recommendations that bridge the cardiovascular and infectious disease domains.

• Enhancing mRNA Loading in Kidney-Targeted Nanoparticles with

  2026-05-09

  This study explores how incorporating diverse excipients can overcome mRNA loading limitations in polymeric mesoscale nanoparticles designed for kidney-targeted delivery. By systematically comparing formulations and evaluating encapsulation, cytotoxicity, and functional performance, the research provides actionable insights for optimizing nanoparticle-mediated gene therapies for renal disorders.

• EZ Cap™ Human PTEN mRNA (ψUTP): Transforming Functional Rest

  2026-05-08

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP) advances in vitro transcribed mRNA technology for durable PTEN restoration and suppression of RNA-mediated innate immune activation. This article uniquely dissects mechanistic insights and experimental best practices, empowering translational cancer research.

• SU6656 Src Tyrosine Kinases Inhibitor: Protocols & Innovatio

  2026-05-08

  SU6656, a selective Src tyrosine kinases inhibitor from APExBIO, is redefining both cancer research and hiPSC-derived platelet workflows by enabling precise signaling control and workflow cost reduction. This article translates high-impact findings into actionable protocols, troubleshooting strategies, and future-facing research opportunities.

• Antipyrine in Translational Research: Gold-Standard for BBB

  2026-05-07

  This thought-leadership article explores Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) as a benchmark compound for pain and fever mechanism studies, focusing on its role in pharmacokinetic modeling and blood-brain barrier (BBB) permeability assessments. By integrating mechanistic insights, experimental design strategy, and the latest high-throughput BBB model advances, the article guides translational researchers in leveraging Antipyrine for reproducible, decision-driving CNS workflows. The discussion bridges literature-backed protocols, product intelligence from APExBIO, and real-world laboratory scenarios, setting a new standard for the deployment of legacy compounds in modern drug metabolism research.

• Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer

  2026-05-07

  Gu et al. demonstrate that combining CDK4/6 and BET inhibitors yields synergistic suppression of pancreatic tumor growth and epithelial-to-mesenchymal transition (EMT) by targeting the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight provides a rationale for dual-targeted approaches in overcoming resistance and limiting metastasis in pancreatic ductal adenocarcinoma.

• Novel Allosteric PDK4 Inhibitors Advance Metabolic Disease T

  2026-05-06

  This study identifies a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors with nanomolar potency and favorable pharmacokinetics, providing a promising scaffold for metabolic disease intervention. The lead compound demonstrated efficacy in models of glucose intolerance, allergy, and cancer, suggesting broad therapeutic relevance.

• SGC-CBP30: Precision Epigenetic Tool for CREBBP/EP300 Inhibi

  2026-05-06

  SGC-CBP30 empowers researchers to dissect epigenetic mechanisms driving cancer progression, with validated utility in super-enhancer hijacking and TGF-β/SMAD3 pathway studies. This guide details optimized experimental workflows, advanced troubleshooting, and actionable insights to maximize its impact in transcriptional coactivator inhibition and lung adenocarcinoma research.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-05-05

  This study demonstrates that increasing GLT-1 expression in mice after traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive dysfunction by inhibiting the CB1-CREB signaling pathway. The findings clarify the mechanistic link between endocannabinoid signaling, glutamate homeostasis, and neuroprotection, supporting targeted research in neurotrauma and cognitive dysfunction.

• Metabolic Intervention to Enhance Ferroptosis and Cuproptosi

  2026-05-05

  This study introduces a metabolic intervention strategy using a nanosystem to simultaneously sensitize tumor cells to ferroptosis and cuproptosis, thereby boosting anti-tumor immunity. The approach targets glycolysis and NAD+ metabolism to amplify regulated cell death, providing a new avenue for cancer therapy and immune modulation.

16060 records 1/1071 page Next 12345 下5页 Last page